Clinical Trials
Sponsor:
Sponsor Study ID:
Study Title:
A Phase 3, Randomized, Open-Label Study To Evaluate the Efficacy and Safety of Eflornithine with Lomustine Compared to Lomustine Alone in Patients with Anaplastic Astrocytoma That Progress/Recur After Irradiation and Adjuvant Temozolomide Chemotherapy
NCT Number:
NCT02796261
Phase:
III
Protocol Type:
Treatment
Age Group:
Adults
Disease Sites:
Brain and Nervous System
Study Objectives:
The primary objectives of this study are to demonstrate superiority in OS and comparable safety when eflornithine is added to lomustine compared to lomustine alone in patients with AA that progress/recur after irradiation and adjuvant temozolomide chemotherapy.
Study Documents
(MUSC NetID required for document access)